Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å undersøke sikkerheten, farmakokinetikken og foreløpig effekt av IDE574-terapi hos voksne deltakere med avanserte solide tumorer

2. november 2026 oppdatert av: IDEAYA Biosciences

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.

The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

Part 1 - Monotherapy Dose Escalation and Expansion:

Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.

Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.

Part 1C - Exploratory Food Effect Sub-study

Part 2 - Combination Dose Escalation and Expansion

Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.

Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A

Studietype

Intervensjonell

Registrering (Antatt)

155

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Santa Monica, California, Forente stater, 90404-2095
        • Aktiv, ikke rekrutterende
        • UCLA - Parkside Cancer Center
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510-3206
        • Rekruttering
        • Yale School of Medicine - Cedar Street
        • Hovedetterforsker:
          • Patricia LoRusso, MD
        • Ta kontakt med:
    • Florida
      • Plantation, Florida, Forente stater, 33322
        • Rekruttering
        • Florida Clinical Trials Group
        • Hovedetterforsker:
          • Harshad Amin, MD
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322-1013
        • Rekruttering
        • Winship Cancer Institute, Emory University
        • Hovedetterforsker:
          • Shipra Gandhi, MD
        • Ta kontakt med:
    • Missouri
      • St Louis, Missouri, Forente stater, 63110-1010
        • Rekruttering
        • Washington University - Siteman Cancer Center
        • Hovedetterforsker:
          • Faisal Fa'ak, MD
        • Ta kontakt med:
    • New Jersey
      • East Brunswick, New Jersey, Forente stater, 08816
        • Rekruttering
        • START Astera, LLC
        • Hovedetterforsker:
          • Bruno Fang, MD
        • Ta kontakt med:
    • New York
      • Lake Success, New York, Forente stater, 11042
        • Rekruttering
        • START New York Long Island, LLC
        • Hovedetterforsker:
          • Geraldine O'Sullivan Coyne, MD
        • Ta kontakt med:
      • New York, New York, Forente stater, 10032-3729
        • Aktiv, ikke rekrutterende
        • Columbia University Medical Center -161 Fort Washington
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • SCRI Oncology Partners - PPDS
        • Hovedetterforsker:
          • Sarah Premji, MD
        • Ta kontakt med:
    • Texas
      • Austin, Texas, Forente stater, 78758
      • Dallas, Texas, Forente stater, 75039
      • Fort Worth, Texas, Forente stater, 76104
        • Rekruttering
        • START Dallas Fort Worth, LLC
        • Hovedetterforsker:
          • Henry Xiong, MD
        • Ta kontakt med:
      • Houston, Texas, Forente stater, 77030-4009
        • Rekruttering
        • MD Anderson Cancer Center
        • Hovedetterforsker:
          • Timothy Yap, MD
        • Ta kontakt med:
      • Houston, Texas, Forente stater, 77054
        • Rekruttering
        • NEXT Texas LLC - Houston
        • Hovedetterforsker:
          • Jennifer Segar, MD
        • Ta kontakt med:
      • San Antonio, Texas, Forente stater, 78229
        • Rekruttering
        • NEXT Texas LLC - San Antonio
        • Hovedetterforsker:
          • David Sommerhalder, MD
        • Ta kontakt med:
      • San Antonio, Texas, Forente stater, 78229
        • Rekruttering
        • Start San Antonio, LLC
        • Hovedetterforsker:
          • Amita Patnaik, MD
        • Ta kontakt med:
    • Utah
      • West Valley City, Utah, Forente stater, 84119
        • Rekruttering
        • START Mountain Region, LLC
        • Hovedetterforsker:
          • William McKean, MD
        • Ta kontakt med:
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
    • K'alak'i T'bilisi
      • Batumi, K'alak'i T'bilisi, Georgia, 6000
        • Rekruttering
        • High Technology Hospital MedCenter Ltd
        • Hovedetterforsker:
          • Tamta Makharadze, MD
        • Ta kontakt med:
      • Tbilisi, K'alak'i T'bilisi, Georgia, 114
        • Rekruttering
        • Pineo Medical Ecosystem
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mziuri Zakaraia, MD
      • Tbilisi, K'alak'i T'bilisi, Georgia, 112
        • Aktiv, ikke rekrutterende
        • LLC ARENSIA Exploratory Medicine
      • Tbilisi, K'alak'i T'bilisi, Georgia, 144
        • Aktiv, ikke rekrutterende
        • Geo Hospitals Multiprofile Medical Center Tbilisi
      • Tbilisi, K'alak'i T'bilisi, Georgia, 186
        • Aktiv, ikke rekrutterende
        • LLC Caucasus Medical Centre

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 99 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Archival Tissue sample for testing

  • Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
  • Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
  • Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
  • Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
  • Have adequate bone marrow, renal and liver function.
  • Life expectancy of >3 months
  • Able to safely administer and retain orally administered study treatment
  • Able to comply with contraceptive/barrier requirements

Key Exclusion Criteria:

  • Known symptomatic brain metastases or leptomeningeal metastasis
  • Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
  • Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
  • Have active liver or biliary disease.
  • Have active, uncontrolled bacterial, fungal, or viral infection
  • Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
  • If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
  • Prior irradiation to >25% of the bone marrow.
  • Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Monotherapy Dose Escalation (Part 1A)

Participants with the appropriate tumor types will be treated with escalating doses of IDE574

IDE574

Eksperimentell: Monotherapy Dose Expansion (Part 1B)

Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574

IDE574

Eksperimentell: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant

Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant

IDE574

Fulvestrant Injection

Eksperimentell: Combination Dose Expansion (Part 2B)

Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant

IDE574

Fulvestrant Injection

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Tidsramme: Following the first dose of IDE574

incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0

Following the first dose of IDE574
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Tidsramme: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Tidsramme: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Tidsramme: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Tidsramme: total study duration

Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Tidsramme: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Tidsramme: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Tidsramme: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration

Sekundære resultatmål

Resultatmål
Tidsramme
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Tidsramme: total study duration
total study duration
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Tidsramme: total study duration
total study duration
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Tidsramme: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Tidsramme: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Tidsramme: total study duration
total study duration
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Tidsramme: total study duration
total study duration

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. mars 2026

Primær fullføring (Antatt)

31. desember 2029

Studiet fullført (Antatt)

31. januar 2030

Datoer for studieregistrering

Først innsendt

1. april 2026

Først innsendt som oppfylte QC-kriteriene

14. april 2026

Først lagt ut (Faktiske)

20. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • IDE574-001
  • 178299 (Annen identifikator: Regulatory Agency Identifier Number (s))

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere